Camille Linot
About Camille Linot
Camille Linot is a Medical Scientist Associate at Kite Pharma, specializing in oncology and cell therapy. With a background in pharmacy and extensive experience in drug biodistribution monitoring and CAR T-cell construct studies, Linot has contributed to advancements in cancer treatment.
Work at Kite Pharma
Camille Linot has been employed at Kite Pharma as a Medical Scientist Associate since 2020. In this role, she has contributed to the development of innovative therapies in the field of oncology and cell therapy. Her responsibilities include establishing protocols for monitoring drug biodistribution using advanced techniques such as fluorescence imaging and MRI on 3D in vitro cell cultures and animal models. This work supports Kite Pharma's mission to advance cancer treatment through cutting-edge research and development.
Previous Experience at Memorial Sloan Kettering Cancer Center
Prior to her current position, Camille Linot worked at Memorial Sloan Kettering Cancer Center from 2018 to 2020 as a Postdoctoral Fellow in the Adusumilli Lab. During her two-year tenure in New York, she focused on oncology research, contributing to the understanding and treatment of cancer. Her experience in a leading cancer research institution has equipped her with valuable insights and skills applicable to her current role.
Education and Expertise
Camille Linot holds a Doctorat and a Master 2 in Pharmacy from Université d'Angers, where she studied from 2006 to 2012. Additionally, she completed a Graduate program in animal experimentation at Ecole nationale vétérinaire de Nantes in 2016. Her educational background also includes a Bachelor's degree in Physique from Lycée Privé Sainte Marie-Cholet. This extensive education has provided her with a strong foundation in pharmaceutical sciences and research methodologies.
Research and Development Contributions
Throughout her career, Camille Linot has made significant contributions to research and development in oncology. She developed a nanodelivery system designed for monitoring drug delivery in solid cancers. Furthermore, she collaborated on clinical-grade CAR T-cell construct Investigational New Drug (IND) studies, which involved experimental plan development and FDA submission. These initiatives demonstrate her commitment to advancing cancer therapies and improving patient outcomes.
Mentorship and Leadership
Camille Linot has demonstrated leadership by mentoring a multidisciplinary team in the field of oncology and cell therapy. Her ability to guide and support colleagues reflects her expertise and commitment to fostering collaboration in research environments. This mentorship role enhances the productivity and innovation of her team, contributing to the overall success of their projects.